EUVIMEDDescoperă EUVIMED
Crossref

Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain

Sumin Kim, Injeoung Hwang, Suhn Hyung Kim, Hwan Won Chung, Mi-Jung Ji, Sojeong Moon, Hyun-Mee Park, Gu Kong, Wooyoung Hur iD

Chemical Biology & Drug Design · 2023

DOI: 10.1111/cbdd.14249 ↗

At a glance

Journal article in Chemical Biology & Drug Design, 2023. Written by Sumin Kim and 8 co-authors. Institution: HY-KIST Bioconvergence, Hanyang University, Seoul, South Korea. Major MEDLINE topics: PR-SET Domains, Breast Neoplasms. Cited 11 times so far (Crossref); 22 references. Funded by: National Research Council of Science and Technology, National Research Foundation of Korea.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

NSD3/WHSC1L1 lysine methyltransferase promotes the transcription of target genes through di‐ or tri‐methylation at histone H3K36 using SAM as a cofactor. Genetic alterations such as amplification and gain‐of‐function mutation of NSD3 act as oncogenic drivers in several cancers including squamous cell lung cancer and breast cancer. NSD3 is an important therapeutic target for cancers, but the reported NSD3 inhibitors targeting the catalytic SET domain are very rare and show a poor activity. Herein, from a virtual library screening and the subsequent medicinal chemistry optimization, we identified a novel class of NSD3 inhibitors. Our docking analysis and pulldown result suggested that the most potent analogue 13i shows a unique, bivalent binding mode interacting with both SAM‐binding site and BT3‐bindig site within the SET domain. We found 13i inhibits NSD3 activity with IC 50 = 287 μM in vitro and suppresses the proliferation of JIMT1 breast cancer cells with GI 50 = 36.5 μM, which express a high level of NSD3. Also, 13i downregulated the levels of H3K36me2/3 in a dose‐dependent manner. Our study could provide an insight in designing high‐affinity NSD3 inhibitors. Also, as the acrylamide group of 13i was predicted to position near Cys1265 in the BT3‐binding site, further optimization would lead to a discovery of novel irreversible NSD3 inhibitors.

Subjects

MeSH terms (MEDLINE)

PR-SET DomainsBreast NeoplasmsHumansFemaleHistonesProtein DomainsMethylation

Author keywords

BT3-binding siteNSD3 histone methyltransferase inhibitorSAM-binding siteSET domainconserved cysteine

Substances

Histones

Authors and institutions

  • HY-KIST Bioconvergence, Hanyang University, Seoul, South Korea.
  • Medicinal Materials Research Center, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
  • Computational Science Research Center, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
  • Advanced Analysis Data Center, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
  • Department of Pathology, Hanyang University College of Medicine, Seoul, South Korea.

ORCID profiles: Wooyoung Hur

Funding

  • National Research Council of Science and Technology
  • National Research Foundation of Korea

Cite

APA

Kim, S., Hwang, I., Kim, S. H., Chung, H. W., Ji, M. J., Moon, S., Park, H. M., Kong, G., & Hur, W. (2023). Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.14249

Vancouver

Kim S, Hwang I, Kim SH, Chung HW, Ji MJ, Moon S, et al. Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain. Chemical Biology & Drug Design. 2023. doi:10.1111/cbdd.14249

BibTeX
@article{Kim2023,
  author = {Kim, Sumin and Hwang, Injeoung and Kim, Suhn Hyung and Chung, Hwan Won and Ji, Mi-Jung and Moon, Sojeong and Park, Hyun-Mee and Kong, Gu and Hur, Wooyoung},
  title = {Identification of novel class inhibitors of NSD3 methyltransferase showing a unique, bivalent binding mode in the SET domain},
  journal = {Chemical Biology & Drug Design},
  year = {2023},
  doi = {10.1111/cbdd.14249}
}
Start for free →